biotechnology

In this paper our aim is to assess the evolution of the Finnish biotechnology sector during the 2000’s. Particular focus is given to the growth expectations and realized outcomes of Finnish biotechnology companies, to the evolution of public investments, and to potential determinants of company performance in the sector. The empirical results suggest that there

The turnover of the companies in North Savo in 2011 was nearly 10 billion euros, of which industry accounted for just under a third. The industrial structure of the region is not strong, but on the other hand it is not alarmingly thin either, because it does have certain successful niches. North Savo’s production and

Väitöskirjassa tunnistetaan ja tarkastellaan mm. liikkeenjohtoon ja toiminnan organisointiin liittyviä haasteita, joita suomalaiset pienet ja keskisuuret bioteknologiayritykset ovat kohdanneet alan kehittyessä teollisuudeksi. Väitöskirja todentaa, että yliopistolähtöiset bioteknologiayritykset ovat muun tyyppisiä bioteknologiayrityksiä heikompia hankkimaan rahoitusta, rekrytoimaan osaavaa työvoimaa ja suunnittelemaan kestäviä liiketoimintamalleja. Publication year: 2011 Pages: 229 Price: 30€ Language: English ETLA A 47

Technological change is one of the key driving forces behind economic growth. In this process, the diffusion of new technologies plays a vital role. In particular, the early stages of diffusion, in which knowledge is created and transferred for wider industrial use, are seen as crucial to the broader societal impact of technologies. Therefore, it

Even with globalization, industrial clusters are maintaining their importance in today’s economy. With the decomposition of production we find that clusters are becoming focused on specific industries and stages of production. This paper analyzes two peripheral western countries, Finland and Israel, which saw success in their ICT clusters and wanted to duplicate this success building

Global health care issues are driving the public sector into a balancing act between conflicting and complementary forces of inevitable change: an ageing population, the explosion of new therapeutic technologies, a critical shortage of clinical professionals, the desire to improve clinical outcomes, and economic constraints. With respect to technology and economic constraints, the public is